AI in Drug Discovery Market Set to Surpass USD 13.2 Billion by 2035, Driven by Generative AI, Multi-Omics and Precision Medicine

The global AI in drug discovery market was valued at US$ 2.1 billion in 2024 and is projected to grow at a CAGR of 18.4% from 2025 to 2035, exceeding US$ 13.2 billion by the end of 2035. The market is being transformed by rapid advances in artificial intelligence (AI), machine learning (ML), generative AI, cloud computing, and large-scale biomedical data analytics.

Get a concise overview of key insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82867

Market Overview: Artificial intelligence is changing the conventional drug discovery process by enabling researchers to analyze extensive chemical, genomic, proteomic, clinical, and real-world datasets at significantly greater speed. Traditional approaches to identifying and optimizing drug candidates can require years of research and substantial investment. AI-based platforms can accelerate virtual screening, target identification, molecular design, drug repurposing, toxicity prediction, and clinical trial planning.

The availability of electronic medical records, heterogeneous omics datasets, imaging repositories, and digital biomarkers is further expanding the amount of information available for computational drug discovery. At the same time, affordable cloud computing and scalable infrastructure are making high-performance computational experimentation more accessible to pharmaceutical companies, biotechnology firms, and research institutions.

Key Drivers of Market Growth

One of the major drivers is the increasing prevalence of chronic diseases, including cancer, cardiovascular disorders, diabetes, and neurological conditions. The growing disease burden is creating demand for faster development of effective therapies while exposing limitations in traditional trial-and-error approaches.

Advancements in AI and ML are another important growth factor. Deep learning models can analyze complex biomedical datasets to identify relationships between genetic markers, disease pathways, molecular structures, and drug responses. These capabilities can support the identification of new targets and improve compound design.

The increasing focus on personalized medicine is also strengthening demand for AI-based approaches. AI can help researchers stratify patients, identify biomarkers, and develop therapies tailored to specific biological characteristics. Growing R&D investment, drug development costs, and the need to reduce late-stage clinical failures are further encouraging adoption.

Emerging Trends

Generative AI is emerging as an important technology in drug discovery. These models can generate novel molecular structures based on desired characteristics, supporting faster hit discovery and compound optimization.

Drug repurposing is another growing application. AI can analyze existing drug-related information to identify potential new therapeutic uses, potentially reducing development timelines because established safety information may already be available.

Another notable trend is the integration of multi-omics data. Companies are increasingly combining genomics, proteomics, and metabolomics to obtain a more comprehensive understanding of disease mechanisms and identify potential therapeutic targets.

AI is also expanding into predictive toxicology, pharmacokinetic modeling, virtual screening, and clinical trial design. Cloud-based and hybrid AI platforms are increasingly being developed to provide end-to-end drug discovery capabilities.

New Opportunities and Challenges

The expansion of real-world evidence and advances in computational biology are creating significant opportunities for AI-enabled drug discovery. Collaboration between pharmaceutical companies, biotechnology startups, technology providers, academic institutions, and research consortia is also opening new avenues for innovation.

However, data quality, interoperability, privacy, model transparency, validation, and regulatory acceptance remain important challenges. Reliable AI applications require high-quality and representative datasets. Companies therefore continue to invest in data governance, validation processes, proprietary algorithms, and collaborative research models.

Buy this Premium Research Report for exclusive, in-depth insights - https://www.transparencymarketresearch.com/checkout.php?rep_id=82867<ype=S

Regional Insight

North America currently dominates the global AI in drug discovery market, supported by advanced healthcare and technology infrastructure, extensive biomedical datasets, established pharmaceutical and biotechnology industries, and significant venture capital and government funding.

The region also benefits from strong collaboration among pharmaceutical companies, technology providers, academic institutions, and research organizations. Europe and Asia Pacific are also expected to offer substantial growth opportunities as investments in AI, biotechnology, precision medicine, and digital healthcare expand.

Competitive Landscape

The competitive environment is evolving as pharmaceutical companies, biotech startups, technology companies, and research organizations increasingly form strategic partnerships. Market participants are investing in proprietary AI algorithms, multi-omics platforms, generative AI, predictive toxicology, virtual screening, and cloud-based drug discovery solutions.

Prominent companies operating in the market include Merck KGaA, Insilico Medicine, BenevolentAI, Relay Therapeutics, Atomwise Inc., DEEP GENOMICS, ZS, Recursion, Verge Genomics, Benchling, BioAge Labs, Inc., Curia Global, Inc., StoneWise, Genesis Therapeutics, Valo Health, IKTOS, MAbSilico, Elix, Inc., and Google LLC.

Recent developments also highlight the industry's movement toward collaborative AI ecosystems. In July 2025, Elix and the Life Intelligence Consortium announced commercialization of an AI drug discovery platform using federated learning across data owned by multiple drug companies. In March 2025, Google announced TxGemma, a suite of AI models designed to support evaluation of therapeutic candidates during early-stage drug research.

Future Outlook

The AI in drug discovery market is expected to maintain strong growth through 2035 as pharmaceutical and biotechnology companies seek to improve research efficiency, reduce development risks, and accelerate innovation. Generative AI, multi-omics analysis, precision medicine, automated experimentation, and cloud-based platforms are expected to remain important areas of development.

According to the market outlook, the global industry is projected to expand from US$ 2.1 billion in 2024 to more than US$ 13.2 billion by 2035, representing a CAGR of 18.4% between 2025 and 2035.

Important FAQs

How big was the global AI in drug discovery market in 2024?

The global AI in drug discovery market was valued at US$ 2.1 billion in 2024.

How big will the market be in 2035?

The market is projected to exceed US$ 13.2 billion by the end of 2035.

What factors are driving market growth?

Key factors include the rising prevalence of chronic diseases, advances in AI and machine learning, increasing R&D investment, growing adoption of personalized medicine, and the need to improve drug development efficiency.

What will be the CAGR during 2025–2035?

The global AI in drug discovery market is projected to grow at a CAGR of 18.4%.

Who are the prominent market players?

Major companies include Merck KGaA, Insilico Medicine, BenevolentAI, Relay Therapeutics, Atomwise, DEEP GENOMICS, Recursion, Verge Genomics, Valo Health, IKTOS, Elix, Google, and other technology, biotechnology, and pharmaceutical organizations.

Explore Latest Research Reports by Transparency Market Research-

Laboratory Information Systems Market

Operating Room Management Market

Revenue Cycle Management Market

Digital Pathology Market

Patient Engagement Solutions Market

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analyzed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com